The U.S. Food and Drug Administration (FDA) approved Eli Lilly's oral GLP-1 drug, Foundayo (active ingredient: orforglipron), for market release this Wednesday. This marks a significant milestone for Lilly and provides an opportunity to further test the market potential of this new class of weight-loss medications. Following the announcement, Eli Lilly's stock price rose over 5% during the trading day. The once-daily oral medication is expected to begin shipping through Lilly's direct platform, LillyDirect, starting next Monday and will soon be available at major pharmacies and telehealth platforms.
**Hot Topic Tracking** The approval of Eli Lilly's key oral weight-loss drug Foundayo by the FDA signifies a new phase in the competition within the GLP-1 weight-loss drug market. As a once-daily oral formulation, the drug will be distributed via LillyDirect. It features a flexible pricing strategy, with insured patients paying as little as $25 per month, while out-of-pocket costs for self-paying patients range from $149 to $349 monthly depending on dosage. Foundayo's rapid approval was facilitated by the "Priority Review" pathway, granting market authorization just months after application submission, lagging only about three months behind Novo Nordisk's oral version of Wegovy.
Although Foundayo's weight-loss efficacy is slightly lower than Lilly's injectable Zepbound, its oral administration offers a more convenient user experience. It is not constrained by cold chain logistics required for injectables and boasts better scalability for mass production. Analysts project the drug could achieve sales of $14.79 billion by 2030. In preparation, Lilly has invested over $55 billion in manufacturing capacity to support global supply. In China, Lilly has already submitted a market application for the drug and entered a production cooperation agreement with Pharmaron, forming a key part of its $3 billion investment plan in the country.
The approval not only propelled Eli Lilly's stock price upwards by more than 5% but will also test market acceptance for oral weight-loss drugs, initiating a "battle for supremacy" with Novo Nordisk in the oral GLP-1 segment. With the global overweight and obese population continuing to grow, the convenience of oral formulations is expected to further expand the market size, offering patients more treatment options.
**Hot Topic Analysis** The FDA approval of Eli Lilly's oral GLP-1 drug Orforglipron (brand name: Foundayo) represents a major advancement in the GLP-1 receptor agonist field. This once-daily small molecule oral medication can be taken at any time of day without restrictions related to food or water intake, significantly improving ease of use.
According to results from Lilly's Phase 3 clinical trials, ATTAIN-MAINTAIN, Orforglipron met all primary and key secondary endpoints, demonstrating superior weight maintenance compared to a placebo. The drug will be shipped via LillyDirect and is expected to be available shortly at major pharmacies and telehealth platforms, potentially enhancing market accessibility rapidly.
This approval validates the commercial potential of small molecule oral GLP-1 drugs, providing a new treatment option for obesity. By differentiating its delivery method, Lilly further solidifies its leading position in the metabolic disease arena, and its market performance warrants continued attention.
**Investment Thesis** The FDA approval of Eli Lilly's oral GLP-1 drug Foundayo is a significant positive development, marking a major breakthrough for Lilly in the weight-loss drug sector. The convenience of this once-daily oral formulation, unrestricted by meals or water intake, is expected to help capture market share through a flexible pricing strategy, with costs for insured patients as low as $25 per month. Foundayo's rapid approval via the Priority Review pathway, coming just about three months after its main competitor, demonstrates strong competitiveness. Lilly has invested $55 billion to expand production capacity for global supply, with analysts forecasting sales reaching $14.79 billion by 2030. The oral dosage form, unhindered by cold chain requirements, offers better scalability for mass production, potentially opening further market opportunities. A market application has been submitted in China, alongside a production partnership with Pharmaron, integral to Lilly's $3 billion investment plan there. Given the persistently growing global population affected by overweight and obesity, the convenience of oral formulations is poised to drive market expansion, providing Lilly with long-term growth momentum.
**Related ETFs** The HuaBao HK Stock Connect Innovative Drug ETF (520880) is fully invested in companies focused on innovative drug R&D. Its top ten holdings include Akeso, Innovent Biologics, CSPC Pharmaceutical Group, BeiGene, Sino Biopharmaceutical, Hansoh Pharma, 3SBio, Kelun-BTB Biopharmaceutical, Duality Biologics, and Remegen, with a combined weighting of 69.66%.
The HuaBao Pharmaceutical ETF (562050) focuses on A-shares in innovative drugs while also including traditional Chinese medicine. Its top ten holdings are Hengrui Pharmaceuticals, Zhejiang NHU, Yunnan Baiyao, Zhangzhou Pien Tze Huang, Kelun Pharmaceutical, Salubris, Fosun Pharma, Huadong Medicine, Changchun High & New Tech Industry Group, and BeiGene, with a combined weighting of 47.80%.
*Data Source: CSI Index Company, Shanghai, Shenzhen, and Hong Kong Stock Exchanges, etc. Note: ETF funds do not charge sales service fees. When investors subscribe for or redeem fund shares, subscription/redemption agents may charge a commission of up to 0.5%, which includes relevant fees charged by stock exchanges and registration institutions. Fund fee rates are detailed in the respective fund legal documents.*
*Risk Disclosure: Index constituents listed are for illustrative purposes only. Descriptions of individual stocks are not intended as investment advice of any form and do not represent the holdings or trading动向 of any fund managed by the fund manager. The fund manager assesses the risk rating of the Pharmaceutical ETF HuaBao and its feeder fund as R3-Medium Risk, suitable for Balanced (C3) and above investors. The risk rating of the HK Stock Connect Innovative Drug ETF HuaBao and its feeder fund is assessed as R4-Medium-High Risk, suitable for Aggressive (C4) and above investors. Any information appearing herein (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and any form of expression) is for reference only. Investors are solely responsible for any independent investment decisions. Furthermore, any views, analysis, or predictions herein do not constitute investment advice of any kind to the reader, and no liability is accepted for any direct or indirect losses resulting from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of this fund. Past performance of a fund is not indicative of its future performance. Fund investment carries risks.*
*A bullish MACD crossover signal has formed, and these stocks are performing well!*
Comments